COmbination Strategy on renal function of the benidipine or diuretics treatMent with RAS inhibitOrs in CKD hypertensive population - COmbination Strategy on renal function of the benidipine or diuretics treatMent with RAS inhibitOrs in CKD hypertensive population (COSMO-CKD)

COSMO-CKD Study Group0 个研究点目标入组 400 人开始时间: 2009年7月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Patients who apply any of the flowing condition cannot participate 1. Outpatient systolic BP is equal or more than 180 mmHg and/or outpatient diastolic BP is equal or more than 110 mmHg. Or hypertensive emergency that requires intravenous administration of antihypertensives 2. Administration of adrenocorticosteroidal drug, immunosuppressant or long-term (equal or more than 2 weeks) administration of non-steroid anti-inflammatory drugs (NSAID) 3. Past history of severe side effect of CCB, thiazide diretic, ARB or ACE inhibitor 4. Type 1 diabetes and type 2 diabetes required hospitalization due to high hemoglobin A1c (equal and more than 9.0%), extremely high blood glucose, or diabetic ketoacidosis 5. Cerebrovascular disease occurs within 6 months 6. Sever heart failure (NYHA class is equal or more than III), severe arrhythmia (frequent ventricular or atrial extrasystole, prolonged ventricular tachycardia, atrial tachyrhythmia with severe tachycardia, atrial fibrillation or flutter with severe tachycardia, sick sinus syndrome with severe bradycardia, atrio-ventricular block with severe bradycardia), angina, or myocardial infarction within 6 months 7. AST or ALT is more than 5 times higher upper limits 8. Pregnant, possible to be pregnant, or willing to be pregnant 9. Patients who are inadequate by determination of physician in charge

发起方

COSMO-CKD Study Group